Streetbeat News

Revenues

MTNB

Matinas BioPharma Holdings, Inc. (MTNB) announced that its Chief Medical Officer, James J. Ferguson, M.D., will present two abstracts at the ASGCT 27th Annual Meeting, showcasing the effectiveness of its LNC platform in delivering small oligonucleotides. The presentations will cover data from ex vivo, in vitro, and in vivo studies demonstrating the LNC platform's potential in targeted delivery for therapeutic purposes, including a focus on inflammatory disease models.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 12:04 pm

GCMG

GCM Grosvenor (NASDAQ:GCMG) reported Q1 2024 earnings of $0.14 per share, meeting analyst estimates and marking a 40% increase from the previous year. However, their sales of $108.866M fell short of the expected $113.367M, a miss by 3.97%, though it's a 9.84% increase from last year.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 12:03 pm

HRTX

Heron Therapeutics has reaffirmed its fiscal year 2024 revenue forecast to be between $138.0 million and $158.0 million, which is in line with the estimated $144.875 million.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 12:03 pm

ACM

AECOM (NYSE:ACM) has received varied analyst ratings over the past three months, with a recent shift towards more bullish perspectives. The average 12-month price target for AECOM has increased to $107.4, reflecting a 6.07% rise from the previous target. Analysts from firms like Baird, Citigroup, and Barclays have raised their price targets, indicating a positive outlook on AECOM's performance. The company has shown significant revenue growth and a strong market position, despite challenges in net margin and debt management.

Portfolio Pulse from Benzinga Insights

May 07, 2024 | 12:01 pm

IFF

Intl Flavors & Fragrances (NYSE:IFF) received varied analyst ratings, with a recent shift towards more positive evaluations. The average 12-month price target was raised to $89.31, indicating a bullish sentiment. The company, a global leader in specialty ingredients, faces challenges with a -4.96% revenue decline and below-average profitability metrics. Despite this, its lower debt-to-equity ratio suggests a stable financial structure.

Portfolio Pulse from Benzinga Insights

May 07, 2024 | 12:01 pm

SGH

SMART Global Holdings (NASDAQ: SGH) has received updated analyst ratings, indicating a positive outlook with an average 12-month price target of $27.12, reflecting an 8.48% increase from the previous target. Analysts from Needham and Stifel have maintained or raised their ratings, citing the company's solid revenue growth, impressive net margin, and effective asset utilization. Despite a high debt-to-equity ratio, SGH's financial health appears robust, with a notable performance in revenue growth and profitability metrics.

Portfolio Pulse from Benzinga Insights

May 07, 2024 | 12:00 pm

WES

Western Midstream (NYSE:WES) has received varied analyst ratings over the last three months, with a recent shift towards a more bullish outlook. Four analysts have updated their ratings, leading to an increase in the average 12-month price target to $35.75, up from $31.50. This reflects a 13.49% increase and is based on improved company performance and market conditions. Western Midstream, engaged in midstream energy assets, has shown notable revenue growth, a high net margin, and strong ROE and ROA, despite a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

May 07, 2024 | 12:00 pm

AORT

Artivion (NYSE:AORT) has received consistent bullish ratings from 4 analysts over the past quarter, with a recent update showing an average 12-month price target of $25.5, marking a 10.87% increase from the previous target of $23. The company has shown impressive revenue growth of 17.98% as of December 31, 2023, and outperforms industry standards in net margin and ROE, despite challenges in debt management.

Portfolio Pulse from Benzinga Insights

May 07, 2024 | 12:00 pm

TDC

Analysts have varied opinions on Teradata (NYSE:TDC), with recent ratings ranging from bullish to bearish. Over the past quarter, sentiments have shifted, with a notable decline in the average 12-month price target from $55.62 to $49.11, reflecting a 11.7% decrease. Analyst actions include lowering and raising price targets, indicating a dynamic perception of Teradata's market position. Despite this, Teradata's financial performance shows challenges in revenue growth, profitability, and debt management compared to industry peers.

Portfolio Pulse from Benzinga Insights

May 07, 2024 | 12:00 pm

GOLF

Acushnet Holdings has reaffirmed its full-year 2024 outlook, expecting net sales to range between $2.450 billion and $2.500 billion, closely aligning with the $2.47 billion estimate. The company also projects its adjusted EBITDA to be approximately $385 million to $405 million.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 11:56 am